T611

DB06391ExperimentalSmall molecule

T611 is an investigational oral anti-cytomegalovirus (CMV) drug candidate.

Mechanism: T611 is an oral anti-cytomegalovirus (CMV) drug candidate. T611 inhibits a CMV enzyme that is essential for viral replication. The new study will explore the efficacy of T611 in HIV/AIDS patients with CMV infection. CMV is a ubiquitous herpes virus that causes serious disease in immuno-compromised patients.
Curator reviewed
Primary indication: Investigated for use/treatment in viral infection and cytomegalovirus (CMV) retinitis.Curator reviewed
Formula / weight: C₁₉H₂₂N₆O₆S · 462.48 g/mol (avg)
Also known as: 2-(3S-3-METHYLMORPHOLINO)-4-(IMIDAZOL-1-YL)-6-METHYL-5-NITROPYRIMIDINE BENZENESULFONATE · BENZENESULFONIC ACID; (3S)-4-(4-IMIDAZOL-1-YL-6-METHYL-5-NITRO-PYRIMIDIN-2-YL)-3-METHYL-MORPHOLINE · MORPHOLINE, 4-(4-(1H-IMIDAZOL-1-YL)-6-METHYL-5-NITRO-2-PYRIMIDINYL)-3-METHYL-, (3S)-, BENZENESULFONATE (1:1)
Code names: AIDS-111759 · T-2611 · T-611

Resolves to

Compound

Structure

InChIKeyGPJYNQNPOAOBPJ-FVGYRXGTSA-NSMILESOS(=O)(=O)C1=CC=CC=C1.[H][C@]1(C)COCCN1C1=NC(C)=C(C(=N1)N1C=CN=C1)N(=O)=O

Targets

What you can answer from here — as of March 06, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

Which drugs share a target with T611, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.